MFX

MFX is a private, pre-revenue platform company developing the Cyto Engine™, an integrated hardware and software system designed to automate and scale cell and gene therapy manufacturing. The platform combines scalable bioreactor cassettes, real-time process analytics, and machine learning to provide precise control over the cellular microenvironment from research through commercial production. By targeting critical bottlenecks in the advanced therapy manufacturing sector, MFX positions itself as an enabler for the broader industry, aiming to reduce costs and increase the reliability of these complex therapies. The company is led by a team with scientific, engineering, and commercial expertise in bioprocessing and cell therapy.

The Cyto Engine™: An integrated hardware and software platform for automated, scalable cell and gene therapy manufacturing. It combines single-use bioreactor cassettes, real-time Process Analytical Technology (PAT), and machine learning-driven analytics for bio-adaptive culture control.

MFX competes in the CGT manufacturing technology space against established bioreactor companies (e.g., Sartorius, Thermo Fisher), specialized automation firms (e.g., Lonza, Miltenyi), and a growing number of startups. Its differentiation hinges on the full integration of scalable hardware, real-time analytics, and adaptive software control in a single platform.